Introduction
Myelination of the CNS is a tightly controlled process, with mature oligodendrocytes providing myelin sheaths to axons and dendrites after proliferation and differentiation from glial precursor cells (Bradl and Lassmann, 2010) . Hypomyelinating leukodystrophies are genetically heterogeneous conditions with overlapping clinical and neuroimaging features that reflect variable abnormalities in myelin formation rather than destruction (Steenweg et al., 2010; Pouwels et al., 2014) . The canonical hypomyelinating leukodystrophy, Pelizaeus-Merzbacher disease, which is caused by alterations in PLP1, a gene encoding a primary constituent of myelin, initially led to speculation that these disorders would be caused by genes encoding myelin proteins. However, recent identification of a series of disease genes associated with hypomyelination (e.g. POLR3A, POLR3B, POLR1C, GJC2, GJB1, TUBB4A, DARS, RARS, AARS, FAM126A, and SOX10) (Zara et al., 2006; Henneke et al., 2008; Osaka et al., 2010; Bernard et al., 2011; Tétreault et al., 2011; Simons et al., 2013; Taft et al., 2013; Dallabona et al., 2014; Wolf et al., 2014; Thiffault et al., 2015) has yielded a more complex view of this group of diseases, implicating different cellular processes all resulting in aberrant oligodendrocyte function as the underlying mechanisms of disease. Amongst these, transcriptional control of myelin genes is of particular relevance. The implication of defective function of SOX10, a transcription factor controlling the expression of several myelin genes (e.g. MBP, PLP1, MAG, GJB1, and GJC2) (Wegner, 2008) , in hypomyelination suggests that aberrant function of other transcription factors modulating expression of these genes may be relevant in this group of disorders (Osaka et al., 2010) .
The homeobox protein NKX6-2 is a transcription factor regulating multiple developmental processes. It is expressed in the developing vertebrate nervous system as well as in the adult brain (Lee et al., 2001) , particularly in areas rich in oligodendrocyte cell bodies and astrocytes. Multiple lines of evidence consistently indicate a relevant role of NKX6-2 in oligodendrocyte function and regulation of myelin gene expression (Cai et al., 2010) . NKX6-2 has also been demonstrated to be involved in other developmental processes, including the regulation of early fate choice of pancreatic progenitors (Schaffer et al., 2010) .
Despite its importance in myelination and cell fate determination for multiple lineages, NKX6-2 has not been associated with a human disease thus far. Here, we report that biallelic inactivating mutations specifically affecting the highly conserved homeobox domain of this transcription factor cause a severe hypomyelinating leukodystrophy.
Materials and methods

Subjects
The study included five affected individuals from three unrelated families. Approval from the institutional ethical committees of the three participating centres was obtained for the genetic studies, and written informed consent was secured from the guardians of all the patients. Families 1 and 2 were consanguineous marriages ( Supplementary Fig. 1 ). Affected individuals were examined by experienced neurologists at their primary care centres, and clinical and imaging data were jointly reviewed. Genomic DNA specimens were obtained from circulating leucocytes using standard procedures. Primary fibroblasts were also obtained from Patients 1 and 2 by dermal skin biopsy.
Molecular genetic analysis
Karyotype or CGH-array analyses were unremarkable in Patients 2 and 4. GJC2 and PLP1 mutation screening, and PLP1 duplication/deletion analysis were performed in Patients 1, 2 and 4, ruling out the occurrence of mutations or functionally relevant variants.
Family 1 was originally screened by a Nextera custom enrichment panel (Illumina) covering promoters, coding regions, exon-intron boundaries, and UTR regions of all known hypomyelination leukodystrophy-related genes (complete list of genes available upon request). Subsequently, a trio-based whole exome sequencing (WES) analysis was performed. Sequencing details and WES data analysis and output are reported in the Supplementary material and Supplementary Table 1. WES data analysis and variant filtering and prioritization were performed using an in-house implemented pipeline as previously reported (Supplementary material).
In Family 2, based on the occurrence of consanguinity in the family ( Supplementary Fig. 1 ), homozygosity mapping was performed. The two affected children together with both parents and a healthy sibling were genotyped using the 250K SNP array (Affymetrix). The analysis provided evidence for the presence of three major homozygous regions shared by the two affected children [a 6.8 Mb region on chromosome 1 (chr1: 53109325-59986107), a 27 Mb region on chromosome 5 (chr5: 74289697-101900036), and a 4.8 Mb region on chromosome 10 (chr10: 130237956-135126644)]. WES was subsequently performed in one affected sibling and his mother by IntegraGen SA as previously described (Supplementary material and Supplementary Table 2). Among the high quality variants, only those that had been annotated as homozygous changes in the patient and at the heterozygous state in the mother were further considered and prioritized.
In Family 3, the two affected individuals and both parents underwent WES. Sequencing details and WES data analysis and output are reported in the Supplementary material and Supplementary Table 3 . WES data analysis and variant filtering and prioritization were performed using an in-house implemented pipeline as previously reported (Supplementary material).
Sanger sequencing was used to validate all NKX6-2 variants and confirm their cosegregation with disease ( Supplementary  Fig. 1 ).
Results
Clinical and imaging characterization
Clinical and electrophysiological features are summarized in Table 1 . All children from the three families included in the study were born at term with normal parameters after uneventful pregnancies and delivery. First signs of disease appeared in the first year of life after an apparently normal neonatal period. Four individuals (Patients 1-4) presented with nystagmus between 1 and 3 months; Patient 5 presented with gross motor delay at the age of 6 months. Patients 1, 2 and 4 had severe motor delays, and never achieved head control. Patients 3 and 5 acquired the ability to reach but not grasp, and Patient 5 was the only one able to roll and pronounce some words. During the first year, all individuals manifested rigid hypertonia quickly followed by severe dystonia in Patients 1-3, needing chemodenervation or pharmacologic management in these patients. A gastrostomy tube was placed for failure to thrive and swallowing difficulties in Patients 1, 2 and 4. During the follow-up, poor visual acuity and pale optic disks appeared in four patients, and the two older patients, Patients 2 and 3, developed progressive musculoskeletal contractures and gingival hypertrophy, the latter not clearly related to any chronic drug effect. All patients had normal orbitofrontal head circumference (OFC) at birth, and none had epilepsy. Patients 1, 2 and 3 showed relative reduction of OFC at follow-up. Patients 1 and 2 developed transitory respiratory failure or apnoeic episodes at age 2 and 1 years, respectively, and Patient 2 died at the age of 16.5 months due to respiratory failure.
Available MRI images were reviewed (D.R. and A.V.). Only Patients 2 and 4 had serial images over time. The brain appeared structurally normal in all individuals. All patients had increased T 2 signal with more normal appearing T 1 signal, which was consistent with hypomyelination (Steenweg et al., 2010) . Signal abnormalities were more prominent in the periventricular and deep white matter, with relatively more normal appearing signal in the subcortical white matter (Fig. 1) . There was higher T 2 signal in the peri-atrial white matter with mild T 1 hypointensity. The MRI images performed at younger ages (Patient 2 at 8 and 14 months, and Patient 3 at 13 months) showed a mildly increased signal of the thalamus, which evolved to an increased signal limited to the anterior nucleus of the thalamus (Patient 2), and was consistently seen only in this region in Patients 1 and 4 (27 months to 5 years of age). The posterior limb of the internal capsule, corpus callosum and brainstem had relatively normal T 1 and T 2 signals, although the middle cerebellar peduncles appeared relatively hypomyelinated. Atrophy of the cerebellar vermis was recognized from the age of 5 years in two patients from whom imaging was available at older ages (Patients 1 and 2), and diffuse atrophy was observed to develop over time in one (Patient 2). Neurophysiological investigations performed in Patients 1 and 2 were concordant with hypomyelination, showing delayed or absent evoked potentials. Available electroretinogram and electroneuromyographic data were also available for these two patients and provided normal findings (Table 1) .
In Patients 1, 2 and 4 a comprehensive metabolic workup, which also included respiratory chain analyses in patients' fibroblasts (Patients 1 and 2) and mitochondrial DNA analysis (Patient 4), was unremarkable, except for an elevated glycine in the urine of Patient 2 (associated with a normal CSF to plasma ratio). Finally, assessment of the amylase level and oral glucose tolerance test in Patient 1 and amylase level in Patient 2 documented no evidence of pancreatic dysfunction.
Exome sequencing analysis
In Family 1, WES variant filtering and prioritization allowed exclusion of excellent candidate disease genes with variants compatible with X-linked or autosomal dominant transmission, while a homozygous change in NKX6-2 [c.606delinsTA, NM_177400.2; p.(Lys202Asnfs*?), NP_796374.1], predicting a frameshift within the homeobox domain, was identified as the only excellent candidate as the causative event underlying the trait (Fig. 2A) . Based on the informative annotated WES variants flanking the c.606delinsTA change, the haplotype shared by the two parents was estimated to cover $3.4 Mb (chr10:131967693-135381927). Genome-wide homozygosity analysis confirmed the consanguineous status of the proband's parents (Supplementary Fig. 2) . The c.606delinsTA variant is predicted to result in a higher molecular weight protein characterized by a sequence diverging at the C-terminus and lacking the C-terminal portion of the DNA binding domain. The variant had previously not been reported in public (dbSNP147 and ExAC v.0.3) and in-house (4700 population-matched exomes) databases. In Family 2, prioritization of all high quality, private/ rare, functionally relevant variants occurring at the homozygous state in the patient and as heterozygous changes in the mother allowed identification of NKX6-2, which was localized within one of the major critical regions identified by homozygosity mapping, as the only one putative disease gene. A homozygous single nucleotide change (c.565G4T) affecting exon 2 was predicted to introduce a stop codon (p.Glu189*) within the homeobox domain and premature protein termination. The variant had not previously been annotated in public databases.
In Family 3, WES data filtering and prioritization taking into account recessive inheritance models disclosed the compound heterozygosity for two single nucleotide changes in NKX6-2 shared by the two affected brothers as the best candidate underlying the trait. The maternally inherited variant, c.589C4T, affected exon 3 and resulted in a premature stop codon (p.Q197*) within the homeobox domain. The paternally inherited variant (c.599G4A) also involving a codon in exon 3, results in a non-conservative missense change (p.R200Q). Both variants were private. The missense mutation, p.R200Q, affected a highly conserved arginine residue directly involved in DNA binding, making hydrogen bonds with DNA backbones from two non-specific nucleotides at the 5' flanking region of the promoter recognition sequence (Fig. 2B) (Chi, 2005; Pradhan et al., 2012) . An arginine at this position is evolutionally conserved in homeodomains (Fig. 2C) , being required for ensuring the correct positioning and orientation of helix 3 of the homodomain and efficient DNA binding, and represents the residue most frequently mutated by disease-causing missense mutations affecting homeodomains (Chi, 2005) . Consistently, a large amount of biochemical data has demonstrated greatly reduced DNA binding and transcriptional activity properties in mutants with substitution of this residue, despite normal protein expression and stability (Chi, 2005) .
To further explore the clinical variability associated with mutations in NKX6-2 and their molecular spectrum, a clinically heterogeneous cohort including an additional 17 unrelated patients with clinically and genetically unclassified hypomyelination were screened for mutations in the gene by Sanger sequencing. Fifteen children in that cohort had an infantile onset, while two had a milder phenotype. No patient with functionally relevant variants was identified, suggesting a specific clinical phenotype of impaired NKX6-2 function to patients with very early onset hypomyelination.
Consistent with the tissue-restricted expression pattern of the gene (http://www.proteinatlas.org/ENSG00000148826-NKX6-2/tissue), assays directed to analyse the impact of NKX6-2 variants on transcript processing and protein synthesis and stability using patients' and control fibroblasts failed to amplify any transcript, impairing an experimental evaluation of the functional impact of mutations.
Discussion
NKX6-2 is a homeobox gene that has a pivotal role in postnatal myelination of the CNS white matter (Cai et al., 2010) . It belongs to the large NKX subfamily of transcription factors (Komuro et al., 1993) . Besides NKX6-2, two additional members belonging to the NKX6 subfamily have been described, NKX6-1 (Rudnick et al., 1994) and NKX6-3 (Alanentalo et al., 2006) . During early development both NKX6-2 and NKX6-1 transcription factors play an important role in the determination and differentiation of the neuronal populations of the basal nuclei, the mesencephalon and ventral diencephalon (Moreno-Bravo et al., 2010; Ma et al., 2013) . Late in development, when oligodendrocytes emerge as NG2-positive oligodendroglial progenitor cells, NKX6-2 is expressed together with other major oligodendrocyte fate determinants, such as OLIG1/2, NKX2-2, and SOX10 (Gorris et al., 2015) . While NKX6-1 and NKX6-2 are broadly expressed in ventral positions of the developing CNS, NKX6-3 shows a remarkably selective expression in a subpopulation of differentiating V2 neurons at caudal hindbrain levels (MorenoBravo et al., 2010) .
Homeodomains of the NKX6 family have nearly identical sequences, and only three conserved amino acid changes differentiate NKX6-1 and NKX6-2 (Fig. 2) . In C57BL murine models, loss of NKX6-2 function does not appear to impact gross motor development (Cai et al., 2001) . However, myelination is impaired, leading to impaired motor coordination and CNS nerve conduction and morphologically associated with abnormal CNS paranodes, and ectopic axoglial junctions in juxtaparanodal myelin (Southwood et al., 2004) . Overall, the C57BL Nkx6-2 À/À mouse is mildly affected whilst severe neurological defects and abnormal ultra-structure of myelin sheaths are present in the Nkx6-2 À/À mice carrying an additional heterozygous inactivating mutation in Nkx2-2 (Cai et al., 2010) . Despite the similar expression of NKX6-1 and NKX6-2 in the ventral positions of the developing CNS and their high sequence homology, there are critical differences. NKX6-2 in humans is expressed in differentiated, post-mitotic oligodendrocytes (Awatramani et al., 1997) but is not found in oligodendrocyte precursors or astrocytes (Moreno-Bravo et al., 2010) , suggesting that there is no functional redundancy between these two transcription factors in humans. Moreover, the fundamental role of NKX6-2 in myelination in man is supported by the finding of severe hypomyelination in individuals with loss of NKX6-2.
It should be noted that a careful analysis of possible concomitant hits involving NKX2-2 in the affected subjects of the present cohort was ruled out in all cases, which would support a more stringent requirement for proper NKX6-2 function during human neurodevelopment.
NKX6-2 has been demonstrated to play a key role in early fate determination of pancreatic progenitors (Schaffer et al., 2010) . Specifically, sustained expression of Nkx6-2 has been shown to block cell differentiation of acinar cells by repressing Ptf1a expression. Assessment of pancreatic function in Patients 1 and 2 (normal amylase levels in blood and normal oral glucose tolerance test) does not support pancreatic dysfunction, suggesting that redundancy between transcription factors of the NKX subfamily is different in oligodendrocyte and pancreatic progenitors.
All identified variants were found to cluster within the homeobox domain. These changes are predicted to negatively impact NKX6-2 function, either by impairing protein synthesis or driving accelerated protein degradation, or by affecting proper DNA binding of the transcription factor (Laughon and Scott, 1984) . In view of the narrow cluster of disease-associated variants identified in this study, we cannot exclude that other mutations with a different impact on NKX6-2 function might underlie less severe hypomyelination phenotypes.
NKX6-2 has been hypothesized to play an important role in oligodendrocyte differentiation and regulation of myelinspecific gene expression, and promoters of both MBP and PLP1 genes contain multiple NKX6-2 binding sites Predicted models of wild-type (left) and the disease-associated p.R200Q mutant (right) NKX6-2 homeobox domain bound to DNA. In wildtype NKX6-2, Arg200 directly contribute to the hydrogen bonding network stabilizing binding of the transcription factor to DNA (left). Hydrogen bonds are shown as dashed black lines. This interaction is disrupted by the Arg-toGln substitution (right). NKX6-2 structural models were generated using ModBase (Pieper et al., 2014) , based on PDB template 3A01A (Miyazono et al., 2010) . (C) Multiple alignment of NKX6-2 paralogues obtained by Clustal Omega showing the region encompassing Arg200 (red). The residue is invariably conserved among the human homeobox proteins. (Cai et al., 2001) , possibly explaining the hypomyelinating phenotype in patients with biallelic inactivating mutations in this gene. The finding of individuals with a severe neurodevelopemental phenotype with hypomyelination associated with biallelic mutations in NKX6-2 provides direct evidence of the relevant role of NKX6-2 in CNS development in humans.
